ViiV Sees Cabenuva In Adolescents Addressing Adherence, Psychological Distress

Reducing the frequency of dosing to six times a year instead of daily pills could help reduce some of the psychological trauma teens with HIV face, chief medical officer Harmony Garges told Scrip.

ViiV announced the approval of Cabenuva in adolescents • Source: Alamy

Despite addressing a small market, the US Food and Drug Administration approval of ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) in adolescents could make a big difference in terms of uptake and adherence of HIV therapy in that age group, the company believes, as well as helping to address some of the lingering stigma around HIV and related psychological issues that adolescent patients face.

The FDA approved Cabenuva on 29 March for adolescents living with HIV who are 12 and older and weigh at...